Effect of testosterone replacement therapy on Vitamin D and FGF-23 levels in congenital hypogonadism

Endokrynologia Polska

Volumn 68, Issue 3, 2017, Pages 311-316

  Haymana, Cem ^a   Sonmez, Alper ^a   Aydogdu, Aydogan ^a   Tapan, Serkan ^a   Basaran, Yalcin ^a   Meric, Coskun ^a   Baskoy, Kamil ^a   Taslipinar, Abdullah ^a   Yilmaz, Mahmut Ilker ^a   Azal, Omer ^a  

^a UNIVERSITY OF HEALTH SCIENCES   (Turkey)

Author keywords

Asymmetric dimethyl arginine; Fibroblast growth factor 23; Hypogonadism; Vitamin D

Indexed keywords

CALCIFEDIOL; FIBROBLAST GROWTH FACTOR 23; N(G),N(G) DIMETHYLARGININE; TESTOSTERONE; VITAMIN D; FIBROBLAST GROWTH FACTOR;

ADULT; ANDROGEN THERAPY; ARTICLE; BODY MASS; CLINICAL ARTICLE; COLORIMETRY; CONGENITAL HYPOGONADOTROPIC HYPOGONADISM; CONTROLLED STUDY; ELECTROCHEMILUMINESCENCE; ENDOTHELIUM; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; KOLMOGOROV SMIRNOV TEST; MALE; MILITARY SERVICE; MORBIDITY; MORTALITY; PROTEIN BLOOD LEVEL; VITAMIN BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; DRUG EFFECTS; HORMONE SUBSTITUTION; HYPOGONADISM; YOUNG ADULT;

FIBROBLAST GROWTH FACTORS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; TESTOSTERONE; VITAMIN D; YOUNG ADULT;

EID: 85021062738     PISSN: 0423104X     EISSN: 22998306     Source Type: Journal    
DOI: 10.5603/EP.a2017.0009     Document Type: Article

References (47)

1. Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004; 27(5): 1036-1041, indexed in Pubmed: 15111517.
2. Traish AM, Saad F, Feeley RJ, et al. The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl. 2009; 30(5): 477-494, doi: 10.2164/jandrol.108.007245, indexed in Pubmed: 19342698.
3. Overvad S, Bay K, Bojesen A, et al. Low INSL3 in Klinefelter syndrome is related to osteocalcin, testosterone treatment and body composition, as well as measures of the hypothalamic-pituitary-gonadal axis. Andrology. 2014; 2(3): 421-427, doi: 10.1111/j.2047-2927.2014.00204.x, indexed in Pubmed: 24659579.
4. Foresta C, Ruzza G, Mioni R, et al. Testosterone and bone loss in Klinefelter syndrome. Horm Metab Res. 1983; 15(1): 56-57, doi: 10.1055/s-2007-1018630, indexed in Pubmed: 6832705.
5. Finkelstein JS, Klibanski A, Neer RM, et al. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med. 1987; 106(3): 354-361, indexed in Pubmed: 3544993.
6. Lee DM, Tajar A, Pye SR, et al. EMAS study group. Association of hypogonadism with vitamin D status: the European Male Ageing Study. Eur J Endocrinol. 2012; 166(1): 77-85, doi: 10.1530/EJE-11-0743, indexed in Pubmed: 22048968.
7. Tak YJ, Lee JG, Kim YJ, et al. Serum 25-hydroxyvitamin D levels and testosterone deficiency in middle-aged Korean men: a cross-sectional study. Asian J Androl. 2015; 17(2): 324-328, doi: 10.4103/1008-682X.142137, indexed in Pubmed: 25532570.
8. Nimptsch K, Platz EA, Willett WC, et al. Association between plasma 25-OH vitamin D and testosterone levels in men. Clin Endocrinol (Oxf). 2012; 77(1): 106-112, doi: 10.1111/j.1365-2265.2012.04332.x, indexed in Pubmed: 22220644.
9. Arisaka O, Arisaka M, Nakayama Y, et al. Effect of testosterone on bone density and bone metabolism in adolescent male hypogonadism. Metabolism. 1995; 44(4): 419-423, indexed in Pubmed: 7723663.
10. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19(3): 429-435, doi: 10.1359/JBMR.0301264, indexed in Pubmed: 15040831.
11. Shimada T, Yamazaki Y, Takahashi M, et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol. 2005; 289(5): F1088-F1095, doi: 10.1152/ ajprenal.00474.2004, indexed in Pubmed: 15998839.
12. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol. 2007; 18(6): 1637-1647, doi: 10.1681/ASN.2007010068, indexed in Pubmed: 17494882.
13. Mirza MAI, Hansen T, Johansson L, et al. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant. 2009; 24(10): 3125-3131, doi: 10.1093/ndt/gfp205, indexed in Pubmed: 19429932.
14. Mirza MAI, Larsson A, Lind L, et al. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009; 205(2): 385-390, doi: 10.1016/j.atherosclerosis.2009.01.001, indexed in Pubmed: 19181315.
15. Tripepi G, Kollerits B, Leonardis D, et al. Competitive interaction between fibroblast growth factor 23 and asymmetric dimethylarginine in patients with CKD. J Am Soc Nephrol. 2015; 26(4): 935-944, doi: 10.1681/ ASN.2013121355, indexed in Pubmed: 25150156.
16. Burnett-Bowie SAM, Mendoza N, Leder BZ. Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men. Bone. 2007; 40(4): 913-918, doi: 10.1016/j.bone.2006.10.016, indexed in Pubmed: 17157573.
17. Meric C, Sonmez A, Aydogdu A, et al. Osteoprotegerin, fibroblast growth factor 23, and vitamin D3 levels in male patients with hypogonadism. Horm Metab Res. 2014; 46(13): 955-958, doi: 10.1055/s-0034-1387789, indexed in Pubmed: 25181418.
18. Aydogdu A, Bolu E, Sonmez A, et al. Effects of three different medications on metabolic parameters and testicular volume in patients with hypogonadotropic hypogonadism: 3-year experience. Clin Endocrinol (Oxf). 2013; 79(2): 243-251, doi: 10.1111/cen.12135, indexed in Pubmed: 23278834.
19. Sonmez A, Haymana C, Bolu E, et al. Metabolic syndrome and the effect of testosterone treatment in young men with congenital hypogonadotropic hypogonadism. Eur J Endocrinol. 2011; 164(5): 759-764, doi: 10.1530/EJE-10-0951, indexed in Pubmed: 21325471.
20. Sonmez A, Haymana C, Aydogdu A, et al. Endothelial dysfunction, insulin resistance and inflammation in congenital hypogonadism, and the effect of testosterone replacement. Endocr J. 2015; 62(7): 605-613, doi: 10.1507/endocrj.EJ15-0125, indexed in Pubmed: 25924666.
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6): 499-502, indexed in Pubmed: 4337382.
22. Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med. 2002; 19(7): 527-534, indexed in Pubmed: 12099954.
23. Dupree K, Dobs A. Osteopenia and male hypogonadism. Rev Urol. 2004; 6 Suppl 6: S30-S34, indexed in Pubmed: 16985910.
24. Jackson JA, Kleerekoper M, Parfitt AM, et al. Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. J Clin Endocrinol Metab. 1987; 65(1): 53-58, doi: 10.1210/jcem-65-1-53, indexed in Pubmed: 3584399.
25. Finkelstein JS, Klibanski A, Neer RM, et al. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med. 1987; 106(3): 354-361, indexed in Pubmed: 3544993.
26. Mittan D, Lee S, Miller E, et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002; 87(8): 3656-3661, doi: 10.1210/jcem.87.8.8782, indexed in Pubmed: 12161491.
27. Irwig MS, Irwig MS. Male hypogonadism and skeletal health. Curr Opin Endocrinol Diabetes Obes. 2013; 20(6): 517-522, doi: 10.1097/01. med.0000436185.36717.76, indexed in Pubmed: 24468754.
28. Blomberg Jensen M, Nielsen JE, Jørgensen A, et al. Vitamin D receptor and vitamin D metabolizing enzymes are expressed in the human male reproductive tract. Hum Reprod. 2010; 25(5): 1303-1311, doi: 10.1093/ humrep/deq024, indexed in Pubmed: 20172873.
29. Francis RM, Peacock M, Aaron JE, et al. Osteoporosis in hypogonadal men: role of decreased plasma 1,25-dihydroxyvitamin D, calcium malabsorption, and low bone formation. Bone. 1986; 7(4): 261-268, indexed in Pubmed: 3768204.
30. Corona G, Rastrelli G, Vignozzi L, et al. Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab. 2011; 25(2): 337-353, doi: 10.1016/j.beem.2010.07.002, indexed in Pubmed: 21397202.
31. Rosano GMC, Sheiban I, Massaro R, et al. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res. 2007; 19(2): 176-182, doi: 10.1038/sj.ijir.3901504, indexed in Pubmed: 16943795.
32. Rabijewski M, Papierska L, Kozakowski J, et al. [The relationship between testosterone and dehydroepiandrosterone sulfate concentrations, insulin resistance and visceral obesity in elderly men]. Endokrynol Pol. 2005; 56(6): 897-903, indexed in Pubmed: 16821208.
33. Laaksonen DE, Niskanen L, Punnonen K, et al. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol. 2003; 149(6): 601-608, indexed in Pubmed: 14641004.
34. Kapoor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006; 154(6): 899-906, doi: 10.1530/eje.1.02166, indexed in Pubmed: 16728551.
35. Mårin P, Holmäng S, Gustafsson C, et al. Androgen treatment of abdominally obese men. Obes Res. 1993; 1(4): 245-251, indexed in Pubmed: 16350577.
36. Li JY, Zhu JC, Dou JT, et al. Effects of androgen supplementation therapy on partial androgen deficiency in the aging male: a preliminary study. Aging Male. 2002; 5(1): 47-51, indexed in Pubmed: 12040975.
37. Sonmez A, Taslipinar A, Tapan S, et al. Comment on: Jones et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 Study). Diabetes Care 2011;34:828-837. Diabetes Care. 2011; 34(11): e172; author's reply e173, doi: 10.2337/dc11-1292, indexed in Pubmed: 22025791.
38. Travison TG, Basaria S, Storer TW, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010; 363(2): 109-122, doi: 10.1056/NEJMoa1000485, indexed in Pubmed: 20592293.
39. Xu L, Freeman G, Cowling BJ, et al. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013; 11: 108, doi: 10.1186/1741-7015-11-108, indexed in Pubmed: 23597181.
40. Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013; 310(17): 1829-1836, doi: 10.1001/ jama.2013.280386, indexed in Pubmed: 24193080.
41. Glueck CJ, Wang P. Testosterone therapy, thrombosis, thrombophilia, cardiovascular events. Metabolism. 2014; 63(8): 989-994, doi: 10.1016/j. metabol.2014.05.005, indexed in Pubmed: 24930993.
42. Li G, Oparil S, Kelpke SS, et al. Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro. Circulation. 2002; 106(7): 854-859, indexed in Pubmed: 12176960.
43. Yilmaz MI, Sonmez A, Saglam M, et al. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int. 2010; 78(7): 679-685, doi: 10.1038/ki.2010.194, indexed in Pubmed: 20613714.
44. Gutiérrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009; 119(19): 2545-2552, doi: 10.1161/CIRCULATIONAHA.108.844506, indexed in Pubmed: 19414634.
45. Bouras G, Deftereos S, Tousoulis D, et al. Asymmetric Dimethylarginine (ADMA): a promising biomarker for cardiovascular disease? Curr Top Med Chem. 2013; 13(2): 180-200, indexed in Pubmed: 23470077.
46. Cakir E, Ozcan O, Yaman H, et al. Elevated plasma concentration of asymmetric dimethylarginine that is reduced by single dose testosterone administration in idiopathic hypogonadotropic hypogonadism patients. J Clin Endocrinol Metab. 2005; 90(3): 1651-1654, doi: 10.1210/jc.2004-2045, indexed in Pubmed: 15613405.
47. Leifke E, Kinzel M, Tsikas D, et al. Effects of normalization of plasma testosterone levels in hypogonadal men on plasma levels and urinary excretion of asymmetric dimethylarginine (ADMA). Horm Metab Res. 2008; 40(1): 56-59, doi: 10.1055/s-2007-1004529, indexed in Pubmed: 18176911.